- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07519265
Studio di Bioequivalenza delle Compresse a Rilascio Prolungato di Chiglitazar/Metformina
Studio di Bioequivalenza delle Compresse a Dose Fissa in Formulazione a Rilascio Prolungato di Chiglitazar/Metformina in Soggetti Sani: Uno Studio Randomizzato, in Aperto, a Due Periodi, a Singola Dose, Incrociato in Condizioni di Alimentazione
This is a single-center, randomized, open-label, two-period, two-sequence crossover bioequivalence study under fed conditions. The primary objective is to evaluate the bioequivalence of a single oral dose of the test formulation compared with the reference formulation in the fed state.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
- Droga: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1
- Droga: Chiglitazar tablet, dose 1
- Droga: Metformin extended-release tablet, dose 1
- Droga: Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 2
- Droga: Chiglitazar tablet, dose 2
- Droga: Metformin extended-release tablet, dose 2
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 101300
- Beijing Ditan Hospital, Capital Medical University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy male or female participants;
- Age from 18 to 45 years, inclusive;
- Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
- From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures;
- Voluntarily agrees to participate in the study and signs the informed consent form.
Exclusion Criteria:
- Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
- Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products;
- Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
- Surgery within 3 months prior to screening or planned surgery during the study period;
- Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
- History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
- Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
- Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
- History of drug or substance abuse, or a positive alcohol or urine drug screening test;
- Intolerance to venipuncture, or a history of fainting in response to needles or blood;
- Fasting blood glucose > 6.1 mmol/L or < 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
- Participation in any interventional clinical trial within 3 months prior to screening;
- Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
- Pregnant or lactating women;
- Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
- Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
- Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
- Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
- Glomerular Filtration Rate (GFR) < 90 mL/min/1.73 m²;
- Systolic blood pressure < 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure < 50 mmHg or ≥ 90 mmHg at screening;
- A positive test result at screening for any of the following: Human Immunodeficiency Virus antibody, Treponema pallidum antibody, Hepatitis B surface antigen, or Hepatitis C virus antibody;
- Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
- Plans to or is required to engage in strenuous physical activity or exercise during the study period;
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Sequence T-R (dose 1)
Participants will receive Chiglitazar/Metformin extended-release fixed dose combination tablets at dose level 1 in Period 1 on Day 1, followed by Chiglitazar tablets and Metformin extended-release tablets at dose level 1 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 1. Chiglitazar tablet administered as one of the reference treatment at dose level 1. Metformin extended-release tablet administered as one of the reference treatment at dose level 1. |
|
Sperimentale: Sequence R-T (dose 1)
Participants receive chiglitazar tablet and metformin extended-release tablet at dose level 1 in Period 1 on Day 1, followed by chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 1 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 1. Chiglitazar tablet administered as one of the reference treatment at dose level 1. Metformin extended-release tablet administered as one of the reference treatment at dose level 1. |
|
Sperimentale: Sequence T-R (dose 2)
Participants receive chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 2 in Period 1 on Day 1, followed by chiglitazar tablet and metformin extended-release tablet at dose level 2 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 2. Chiglitazar tablet administered as one of the reference treatment at dose level 2. Metformin extended-release tablet administered as one of the reference treatment at dose level 2. |
|
Sperimentale: Sequence R-T (dose 2)
Participants receive chiglitazar tablet and metformin extended-release tablet at dose level 2 in Period 1 on Day 1, followed by chiglitazar/metformin extended-release fixed-dose combination tablet at dose level 2 in Period 2 on Day 1. |
Fixed-dose combination tablet containing chiglitazar and metformin extended-release, administered at dose level 2. Chiglitazar tablet administered as one of the reference treatment at dose level 2. Metformin extended-release tablet administered as one of the reference treatment at dose level 2. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Concentrazione plasmatica massima (Cmax)
Lasso di tempo: Pre-dose e a più punti temporali post-dose fino a 72 ore
|
Pre-dose e a più punti temporali post-dose fino a 72 ore
|
|
Area Sotto la Curva Concentrazione-Tempo nel Plasma dall'istante zero all'ultima concentrazione misurabile (AUC0-last)
Lasso di tempo: Pre-dose e a più punti temporali post-dose fino a 72 ore
|
Pre-dose e a più punti temporali post-dose fino a 72 ore
|
|
Area Under the Plasma Concentration-Time Curve from time zero to infinity (AUC0-∞)
Lasso di tempo: Pre-dose e a più momenti post-dose fino a 72 ore
|
Pre-dose e a più momenti post-dose fino a 72 ore
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Tempo per la Massima Concentrazione Plasmatica (Tmax)
Lasso di tempo: Pre-dose e a più punti temporali post-dose fino a 72 ore
|
Pre-dose e a più punti temporali post-dose fino a 72 ore
|
|
Eliminazione emivita (t1/2)
Lasso di tempo: Pre-dose e a più punti temporali post-dose fino a 72 ore
|
Pre-dose e a più punti temporali post-dose fino a 72 ore
|
|
Clearance Totale Apparente (CL/F)
Lasso di tempo: Pre-dose e a più tempi post-dose fino a 72 ore
|
Pre-dose e a più tempi post-dose fino a 72 ore
|
|
Volume apparente di distribuzione durante la fase terminale (Vz/F)
Lasso di tempo: Pre-dose e a più momenti post-dose fino a 72 ore
|
Pre-dose e a più momenti post-dose fino a 72 ore
|
|
Incidenza di Eventi Avversi (EA)
Lasso di tempo: fino al Giorno 11
|
fino al Giorno 11
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CGZ112
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .